Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P494.

Elderly patients with inflammatory bowel disease under anti-TNF therapy: efficacy and safety

Authors:

T. Lobaton Ortega1,2, S. Vermeire2, V. Ballet2, P. Rutgeerts2, G. Van Assche2, M. Ferrante2, 1Bellvitge University Hospital, Gastroenterology, Barcelona, Spain, 2University Hospital Leuven, Gastroenterology, Leuven, Belgium

P494. High dose intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement
Authors:

J. Millastre1, S. García López1, E. Bajador1, C. Castaño2, M.A. Morales1, M. Chaparro2, F. Gomollón3, J.P. Gisbert2, 1Miguel Servet University Hospital, Gastroenterology, Zaragoza, Spain, 2Hospital de La Princesa, Gastroenterology, Madrid, Spain, 3Hospital Clinico Universitario Lozano Blesa, Gastroenterology, Zaragoza, Spain

P494

Exploring the efficacy of weight-based dosing of thiopurine therapy in relation to metabolite levels at week 12 in patients with Inflammatory Bowel Disease

Authors:

R. Cox, H. Lee, R. Willert*

Central Manchester University Hospital, Gastroenterology, Manchester, United Kingdom

P495.

Efficacy of switching to infliximab in Crohn's disease patients with loss of response to adalimumab

Authors:

H. Peeters1, E. Louis2, F. Baert3, O. Dewit4, J.-C. Coche5, M. Ferrante6, G. Lambrecht7, A. Colard2, A. Van Gossum8, P. Bossuyt9, T. Moreels10, M. De Vos11, 1Hospital AZ Sint-Lucas, Gastroenterology, Gent, Belgium, 2CHU de Liege, Gastroenterologie, Liege, Belgium, 3AZ Delta Roeselare Menen, Gastroenterology, Roeselare, Belgium, 4UCL St-Luc, Gastroenterology, Brussels, Belgium, 5Clinique Saint-Pierre, Gastroenterology, Ottignies, Belgium, 6University Hospital Gasthuisberg, Gastroenterology, Leuven, Belgium, 7AZ Damiaan, Gastroenterology, Oostende, Belgium, 8Hôpital Erasme ULB, Gastroenterology, Brussels, Belgium, 9Imelda Hospital, Gastroenterology, Bonheiden, Belgium, 10University Hospital Antwerpen (UZA), Gastroenterology, Antwerpen, Belgium, 11Gent University Hospital, Gastroenterology, Gent, Belgium

P495. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
Authors:

E. Rodrigues-Pinto1, F. Magro1, J. Santos-Antunes1, F. Vilas-Boas1, S. Lopes1, A. Nunes1, C. Dias2, G. Macedo1, 1Centro Hospitalar São João, Faculdade Medicina Universidade Porto, Gastroenterology department, Porto, Portugal, 2Faculdade Medicina Universidade Porto, Health Decision and Information Science Department, Porto, Portugal

P495

Azathioprine versus mycophenolate mofetil in combination with anti-TNF alpha agents in the management of Crohn's disease

Authors:

W. Eigner*, F. Vafai-Tabrizi, K. Bashir, C. Primas, H. Vogelsang

Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria

P496.

Efficacy of infliximab therapy in acute and sub-acute ulcerative colitis

Authors:

D. Cheema, E. Harrison, M. Nizamuddin, J. Slater, L. Wood, S. Ishaq, S. Cooper, S. de Silva, The Dudley Group NHS Foundation Trust, Gastroenterology, Dudley, United Kingdom

P496. Hemophagocytic syndrome during inflammatory bowel disease (IBD): a serious and unfamiliar complication of immunosuppressive therapy
Authors:

C. Stefanescu1, M. Allez2, G. Cadiot3, M. Fumery4, A. Amiot5, D. Laharie6, G. Savoye7, J.M. Gornet2, P. Seksik8, X. Treton1, H. Duboc9, E. Fort10, C. Bloch-Quyerat11, Y. Bouhnik1, 1Hôpital Beaujon, Clichy, France, 2Hôpital Saint Louis, Paris, France, 3CHU Reims, Reims, France, 4CHU Amiens, Amiens, France, 5Hôpital Henri Mondor, Creteil, France, 6CHU Bordeaux, Bordeaux, France, 7CHU Rouen, Rouen, France, 8Hôpital Saint Antoine, Paris, France, 9Hôpital Louis Mourier, Colombes, France, 10CHR Orleans, Orleans, France, 11Hôpital George Pompidou, Paris, France

P496

Prevalence and reasons for drug non-adherence in a European cohort of ulcerative colitis patients: The UCandME survey

Authors:

S. Vavricka1, R. Hofmann2, X. Guillaume3, G. Rogler1, L. Peyrin-Biroulet4, E. Safroneeva5, A. Schoepfer*6

1University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 2Tillotts, Gastroenterology, Rheinfelden, Switzerland, 3Kantar Health , Research, Montrouge, France, 4CHU de Nancy, Department of Gastroenterology, Vandoeuvre-les-Nancy, France, 5University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 6Centre Hospitalier Universitaire Vaudois, Gastroenterology and Hepatology, Lausanne, Switzerland

P497.

Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6

Authors:

W.J. Sandborn1, B. Feagan2, W. Reinisch3,4, M. Smyth5, J. Xu6, A. Parikh7, I. Fox8, 1University of California San Diego, Division of Gastroenterology, La Jolla, United States, 2Western University/Robarts Research Institute, Robarts Clinical Trials Inc., London, Canada, 3Medical University of Vienna, Internal Medicine/Gastroenterology, Vienna, Austria, 4McMaster University, Audrey Campbell Chair in Ulcerative Colitis, Hamilton, Canada, 5Takeda Development Centre (Europe) Ltd, General Medicine/GI/Renal, London, United Kingdom, 6Takeda Pharmaceuticals International Company, Biostatistics, Cambridge, United States, 7Takeda Pharmaceuticals International, Inc., General Medicine, Deerfield, United States, 8Takeda Pharmaceuticals International Company, Clinical Development, Cambridge, United States

P497. Has the role of a defunctioning stoma for large bowel Crohn's disease changed in the biological era?
Authors:

M. Marti-Gallostra1, P. Myrelid2, R. Lovegrove3, S. Travis4, B. George3, 1Hospital Vall d'Hebron, Colorrectal Surgery, Barcelona, Spain, 2Linköping University Hospital, Colorectal Surgery, Lipköping, Sweden, 3John radcliffe Hospital, Colorectal Surgery, Oxford, United Kingdom, 4John radcliffe Hospital, Gastroenterology, Oxford, United Kingdom

P497

Surgery and hospitalization in inflammatory bowel disease - what has changed in the last 25 years? - Overview of clinical practice in a tertiary referral center

Authors:

P. Sousa*1, P. Santos1, S. Fernandes1, C. Moura1, C. Baldaia1, A. Gonçalves1, P. Moura Santos1, N. Fatela1, A. Valente1, F. Serejo1, J. Malaquias2, L. Correia1, J. Velosa1

1Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal, 2Centro Hospitalar Lisboa Norte, Surgery, Lisbon, Portugal

P498.

Efficacy of anti TNF-treatment for fistulizing Crohn's disease

Authors:

J. Maljaars1, I. Molendijk1, C. Baeten2, R. Veenendaal1, A. Van der Meulen1, 1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Centre, Surgery, Leiden, Netherlands

P498. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study
Authors:

R. Sacco1, A. Romano1, M. Bertini1, G. Federici1, S. Metrangolo1, G. Parisi1, C. Giampietro2, A. Mazzoni2, C. Nencini2, F. Scatena2, G. Bresci1, 1Gastroenterology and Metabolic Diseases, Gastroenterology, Pisa, Italy, 2Pisa University Hospital, Transfusional Center, Pisa, Italy

P498

Final Results of SOLE study: Focus on patient adherence/satisfaction and their correlation with patient worries

Authors:

A. Orlando*1, F. Castiglione2, A. Privitera3, C. Pagnini4, A. Contaldo5, P. Vernia6, P. Usai7, G. Bodini8, A.F. Ciccaglione9, E. Calabrese10, S. Saettone11, A. Michielan12, G. Gualberti13, M.L. Scribano14

1Ospedali Riuniti Villa Sofia Cervello, Internal Medicine, Palermo, Italy, 2Università Federico II, Gastroenterology, Napoli, Italy, 3Azienda Ospedaliera per l'Emergenza "Cannizzaro", Gastroenterology, Catania, Italy, 4Ospedale S. Andrea, Gastroenterology, Roma, Italy, 5Università di Bari, Gastroenterology, Bari, Italy, 6Università La Sapienza, Gastroenterology, Roma, Italy, 7Azienda Ospedaliero Universitaria di Cagliari, Gastroenterology, Cagliari, Italy, 8Ospedale San Martino, Gastroenterology, Genova, Italy, 9Ospedale Civile "S. Spirito", Gastroenterology, Pescara, Italy, 10Università degli Studi di Roma "Tor Vergata", Gastroenterology, Roma, Italy, 11Ospedale S.S. Trinità, Gastroenterology, Borgomanero , Italy, 12Azienda Ospedaliero-Universitaria di Padova, Gastroenterology, Padova, Italy, 13AbbVie srl, Medical Direction, Campoverde, Italy, 14Azienda Ospedaliera San Camillo-Forlanini , Gastroenterology, Roma, Italy

P499.

Efficacy of adalimumab for induction and maintenance of remission in intestinal Behçet's disease

Authors:

A. Yamada, Y. Suzuki, T. Sasaki, M. Katsumata, M. Miyamura, K. Hirayama, N. Arai, H. Kikuchi, R. Iwasa, R. Furukawa, K. Sono, A. Osamura, K. Nakamura, H. Aoki, Y. Yoshimatsu, Y. Tsuda, K. Takeuchi, N. Takada, Toho University, Sakura Medical Centre, Division of Gastroenterology, Department of Internal Medicine, Sakura, Japan

P499. Folate regimen may reduce high homocysteine levels in a Greek cohort of patients with inflammatory bowel disease
Authors:

E. Tsiaousi1, S. Michael1, S. Polyzos1, C. Stergiopoulos1, K. Anastasiadou1, G. Tsarouchas1, I. Romiopoulos1, C. Zavos1, N. Tantsi1, S. Trygonis1, J. Kountouras1, 1Aristotle University of Thessaloniki, 2nd Medical Clinic, Thessaloniki, Greece

P499

Individualized therapy is long-term cost-effective compared to dose intensification in Crohn's disease patients failing infliximab

Authors:

C. Steenholdt*1, J. Brynskov1, O.Ø. Thomsen1, L.K. Munck2, J. Fallingborg3, L.A. Christensen4, G. Pedersen5, J. Kjeldsen6, B.A. Jacobsen7, A.S. Oxholm8, J. Kjellberg9, M.A. Ainsworth1

1Herlev Hospital, Dept of Gastroenterology, Herlev, Denmark, 2Køge Hospital, Dept. of Medical Gastroenterology, Køge, Denmark, 3Aalborg Hospital, Dept. of Medical Gastroenterology, Aalborg, Denmark, 4Aarhus Hospital, Dept. of Hepatology and Gastroenterology V, Aarhus, Denmark, 5Hvidovre Hospital, Dept. of Gastroenterology, Hvidovre, Denmark, 6Odense Hospital, Dept. of Medical Gastroenterology S, Odense, Denmark, 7Aalborg Hospital, Dept. of Medical Gastroenterology, Aalborg , Denmark, 8University of Southern Denmark, Dept of Business and Economics and Centre of Health Economics Research (COHERE), Odense, Denmark, 9KORA, Danish Institute for Local and Regional Government Research, Copenhagen, Denmark

P500.

Efficacy and safety of granulocyte, monocyte/macrophage adsorptive apheresis in steroid-dependent active UC with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 12 weeks

Authors:

A. Dignass1, A. Akbar2, B. Bonaz3, 1Agaplesion Markus Hospital, Department of Medicine I, Frankfurt, Germany, 2St Mark's Hospital, Dept. of Medicine, Harrow, United Kingdom, 3CHU de Grenoble, Clinique Universitaire d'Hépato-Gastroentérologie, Grenoble, France

P500. Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease
Authors:

J.F. Brandse1, M.E. Wildenberg2, J.R. de Bruyn1, G. Wolbink3, M. Lowenberg1, C.Y. Ponsioen1, G.R. van den Brink1, G.R.A.M. D'Haens1, 1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Tytgat Institute for Liver an Intestinal Research, Amsterdam, Netherlands, 3Sanquin Research Laboratory, Amsterdam, Netherlands